Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon May 31, 2019 10:38am
122 Views
Post# 29788522

RE:So far, there's no delays in the Ph. 2b

RE:So far, there's no delays in the Ph. 2bThat should reassure everybody ... and once again, our regular whiners lacked timing.


May 30, 2019

University Health Hospital ("UHN") is the first site to obtain REB approval and commence Study II and is currently screening patients for enrollment in Study II.

The Company is currently working with 3 additional institutional clinical oncology sites, already in the final negotiation phases with the Company, for commencing Study II in their respective organization in 3Q 2019.

Theralase has confirmed a conference call with the Food and Drug Administration ("FDA") to discuss the design and endpoints of Study II, via a Pre-Investigational New Drug ("PIND") meeting in late June 2019. Pending completion of this conference call, the Company plans to submit an Investigational New Drug ("IND") application to the FDA and subject to their final review and approval, the Company will commence on-boarding institutional clinical oncology sites in the United States for Study II.

_______________

Claridge - (5/30/2019 6:56:39 PM) 

So far, there's no delays in the Ph. 2b

It's legitimate to ask some questions.  But at one point, some should master a minimum of things!  There are limits to post nonsense.

TLT came up with guidelines recently.  They wouldn't have, if they were facing bumps or issues!
 
Some also have hard time understanding the recruitment, screening and enrollment processes and how unpredictable they are in terms of length/duration.
 
TLT/UHN have done everything to be ready for that, by networking community clinics, etc ....  Remember also that direct sollicitation of patients BEFORE green light is given to the clinical trial (April 25 in our case) is clearly forbidden by regulatory bodies.
 
You've then seen clinical trials created in the Clinicaltrials.gov db (May 10) and then on UHN clinical trial site (May 24).
 
ClinicalTrials.gov record also mentions this, as posted earlier this week:
 
Screening Period
 
Patients will be qualified for Study entry by review of inclusion and exclusion criteria during the Screening Period, which will last up to 28 days.
 
So no need to go into all sorts of negative scenarios when we're still in the standard/acceptable timeframes.  Anyways, we'll never be given all the insights, even if you're a shareholder, as Eoganacht accurately mentioned.  That has nothing to do with TLT.  All company keep things for themselves, when it's not material info.., competitive issues oblige.

Negativity on this board is probably what brings this stock price lower ... lolll  Like shooting ourselves in our own foot.   

We have especially couple of ignorant regular grumblers that are not even able to provide clear info. about what they bring forwards.  And don't have problems with questions, but we know those that always doubt, that are never satisified, no matter what.

TLT management wants this much more than you and I.  After all, that's their baby, they've put all those years of efforts and hard work into that company.  They want this to advance much faster than you and I.  Believe me.

If you have a problem of trusting Roger, Dr. Mandel, Dr. Lilge, UHN, PMH, etc ..., then just sell and go invest elsewhere that better suit your investor profile.

And despite superficial rants from our regular whiners, TLT has never been a one guy company as TLT has been working hand-in-hand with UHN.  A one-guy company would have be impossbile with an elite partner like UHN.  And impossible for such a complex and innovative R&D project.  And impossible for an oncology related technology.   Go listen to Dr. Lilge's latest presentations if you don't believe me.  For those that took the time to watch them.

Bullboard Posts